Sight Sciences (NASDAQ:SGHT) CTO Sells $21,651.02 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 2,914 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $7.43, for a total value of $21,651.02. Following the completion of the sale, the chief technology officer directly owned 1,923,855 shares in the company, valued at $14,294,242.65. The trade was a 0.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

David Badawi also recently made the following trade(s):

• On Tuesday, January 6th, David Badawi sold 3,695 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total value of $27,638.60.
• On Monday, January 5th, David Badawi sold 3,051 shares of Sight Sciences stock. The stock was sold at an average price of $7.82, for a total value of $23,858.82.

Sight Sciences Trading Down 3.1%

Shares of SGHT traded down $0.24 during mid-day trading on Tuesday, hitting $7.47. 197,717 shares of the company’s stock traded hands, compared to its average volume of 290,394. The company has a quick ratio of 8.93, a current ratio of 9.60 and a debt-to-equity ratio of 0.62. Sight Sciences, Inc. has a 1 year low of $2.03 and a 1 year high of $9.24. The firm has a market capitalization of $394.94 million, a P/E ratio of -8.30 and a beta of 2.42. The business’s 50-day moving average price is $7.52 and its 200-day moving average price is $5.13.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings results on Wednesday, September 8th. The company reported ($0.81) EPS for the quarter. The business had revenue of $12.54 million during the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%. As a group, sell-side analysts forecast that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Sight Sciences

Several large investors have recently made changes to their positions in the business. Long Focus Capital Management LLC boosted its position in shares of Sight Sciences by 1.3% in the 3rd quarter. Long Focus Capital Management LLC now owns 3,193,305 shares of the company’s stock worth $10,985,000 after purchasing an additional 41,797 shares in the last quarter. Millennium Management LLC increased its position in Sight Sciences by 145.2% during the 3rd quarter. Millennium Management LLC now owns 133,846 shares of the company’s stock valued at $460,000 after buying an additional 79,265 shares in the last quarter. Alliancebernstein L.P. raised its stake in Sight Sciences by 5.5% during the third quarter. Alliancebernstein L.P. now owns 34,380 shares of the company’s stock valued at $118,000 after buying an additional 1,800 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Sight Sciences by 99.8% in the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after acquiring an additional 3,785 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Sight Sciences by 1.0% in the third quarter. Dimensional Fund Advisors LP now owns 303,634 shares of the company’s stock worth $1,045,000 after acquiring an additional 3,051 shares in the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Wall Street Zen raised shares of Sight Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th. Lake Street Capital upped their target price on Sight Sciences from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, October 21st. Raymond James Financial set a $9.00 target price on Sight Sciences in a research report on Monday. Piper Sandler set a $9.00 price target on Sight Sciences in a research report on Monday. Finally, Citigroup upped their price target on Sight Sciences from $5.50 to $9.10 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $8.30.

Sight Sciences News Roundup

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Piper Sandler upgraded Sight Sciences to Overweight (from Neutral), a buy-side analyst upgrade that can attract investor interest and buying momentum. Piper Sandler upgrade
• Neutral Sentiment: Despite recent sales, insiders still hold large positions — CEO Paul Badawi (~5.9M shares) and CTO David Badawi (~1.9M shares) retain substantial ownership, which can indicate alignment with long-term value even as they trim stakes. Insider ownership filing
• Negative Sentiment: Clustered insider selling by executives — CEO Paul Badawi, CTO David Badawi, CFO James Rodberg, EVP Brenton Taylor and insider Jeremy Hayden — over Jan. 2–6. Combined disclosed sales total roughly $0.48M across these transactions; each sale was a small percentage (<1%) of the seller’s holdings but the concentrated timing can create downward pressure on the stock. See CEO / executive filings. CEO sale filing CTO sale filing Other insider filings

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.